Aprea Therapeutics Inc. (NASDAQ: APRE) jumped 28.66% after the company announced that its Phase 1/2 study evaluating eprenetapopt treatment with azacitidine and venetoclax in patients with TP52 mutant AML had achieved the pre-specified complete remission efficacy endpoint.  Eprenetapopt achieved primary efficacy endpoint.  The complete remission (CR) rate was 37%. In […]